5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)
Shalabh Singhal(Integrated BioTherapeutics (United States)), Joan T. Merrill(Oklahoma Medical Research Foundation), Coby Hobar, Subhashis Banerjee(Bristol-Myers Squibb (United States)), Chris Crater, John Throup(Bristol-Myers Squibb (United States)), Vaishali Shah(Bristol-Myers Squibb (Germany)), Hoang Giao Nguyen
Cited by 3
Related Papers
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus
|Nature Genetics|2008|317
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus
|Nature Genetics|2011|284
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort
|Genes and Immunity|2011|281